Briefs from primary sources
The stream: Clinical trials
Two-sentence briefs on FDA announcements, Federal Register documents and ClinicalTrials.gov records, each linked to its source.
Machine-summarized from primary sources; not independently reported. How we use automation
Friday, October 2, 2026
-
Intra-Cellular Therapies registers JNJ-99245354 (ITI-1284) in generalized anxiety disorder
This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 705 participants and has a planned start date of September 30, 2026, with a primary completion date of September 20, 2030.
Source: ClinicalTrials.gov registry record, October 2, 2026
-
Boehringer Ingelheim registers study of survodutide in overweight or obesity without diabetes
This study was first posted on ClinicalTrials.gov on October 2, 2026. The Phase IIIb, open-label study plans to enroll 350 participants, with a planned start date of November 7, 2026 and a primary completion date of June 25, 2028.
Source: ClinicalTrials.gov registry record, October 2, 2026
-
Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis
Jiankuan (Suzhou) Biotechnology Company Limited registered a Phase 3 trial of proximod for moderate-to-severe active rheumatoid arthritis. The study plans to enroll 590 participants and is expected to start on October 15, 2026.
Source: ClinicalTrials.gov registry record, October 2, 2026
-
Regeneron registers trial of ALN-CIDEB in Metabolic Dysfunction-Associated Steatotic Liver Disease
This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 1500 participants and plans to start on November 6, 2026, with primary completion on March 3, 2029.
Source: ClinicalTrials.gov registry record, October 2, 2026
-
PT Bio Farma registers Phase 3 trial of in-house recombinant Hepatitis B vaccine at birth dose
This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 270 participants and has a planned start date of October 2026 with a planned primary completion date of February 2027.
Source: ClinicalTrials.gov registry record, October 2, 2026
-
GlaxoSmithKline registers phase 3 trial of mRNA seasonal influenza vaccine
This study was first posted on ClinicalTrials.gov on October 1, 2026. The trial plans to enroll 3000 participants and aims to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine in adults 18-64 years of age.
Source: ClinicalTrials.gov registry record, October 1, 2026
-
Amgen registers Phase 3 study of inebilizumab in primary membranous nephropathy
This study was first posted on ClinicalTrials.gov on October 1, 2026. The study plans to enroll 159 participants and aims to evaluate the efficacy of inebilizumab on PMN disease activity as measured by complete remission.
Source: ClinicalTrials.gov registry record, October 1, 2026
-
Novartis registers Phase IIIb trial of zigakibart + atrasentan in primary IgA nephropathy
This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 340 participants and plans to start December 1, 2026.
Source: ClinicalTrials.gov registry record, September 30, 2026
-
Results posted for ABC008 study in inclusion body myositis
Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 272 participants and completed primary data collection on November 6, 2025.
Source: ClinicalTrials.gov results record, October 1, 2026
-
Results posted for dexmedetomidine study in dementia agitation
Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study, a Phase 3, randomized, double-blind, placebo-controlled trial, enrolled 13 participants and was terminated.
Source: ClinicalTrials.gov results record, October 1, 2026
-
Results posted for SM04554 topical solution study in male androgenetic alopecia
Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 675 participants and completed primary data collection on December 31, 2020.
Source: ClinicalTrials.gov results record, October 1, 2026
-
Results posted for Atacicept study in IgA nephropathy
Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study, a Phase 3, randomized, double-blinded, placebo-controlled trial (NCT04716231), enrolled 428 participants and began on June 29, 2023.
Source: ClinicalTrials.gov results record, October 1, 2026
-
Results posted for phase 3 orforglipron study in type 2 diabetes
Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 546 participants and completed primary data collection on September 15, 2025.
Source: ClinicalTrials.gov results record, October 1, 2026
-
Results posted for estradiol vaginal insert study
Results for this study were first posted on ClinicalTrials.gov on September 30, 2026. The study enrolled 1050 participants and completed primary data collection on March 15, 2024.
Source: ClinicalTrials.gov results record, September 30, 2026
-
Results posted for TAK-881 PK, safety study in primary immunodeficiency diseases
Results for this study were first posted on ClinicalTrials.gov on September 30, 2026. The study enrolled 65 participants and completed primary data collection on January 20, 2026.
Source: ClinicalTrials.gov results record, September 30, 2026
-
Results posted for LicartTM topical system study
Results for this study were first posted on ClinicalTrials.gov on September 30, 2026. The study enrolled 151 participants, started on October 31, 2021, and completed primary data collection on June 30, 2024.
Source: ClinicalTrials.gov results record, September 30, 2026